{
    "clinical_study": {
        "@rank": "25204", 
        "arm_group": {
            "arm_group_label": "Pentavalen", 
            "arm_group_type": "Experimental", 
            "description": "Pentabio Vaccine One dose corresponds to 0.5ml The vaccine shall be given intramuscularly"
        }, 
        "brief_summary": {
            "textblock": "Measure antibody persistence prior to booster administration of Pentabio vaccine."
        }, 
        "brief_title": "Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Number and percentage of children with anti diphtheria, titer and anti tetanus titer >= 0.01\n      IU/ml, anti HBs >=10mIU/ml, anti Hib >=0.15ug/ml prior to booster administration."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children, 18-24 months of age\n\n          -  Subjects who had completed the primary series of Pentabio vaccine in the previous\n             trial\n\n          -  Father, mother, or legally acceptable representative have been informed properly\n             regarding the study and signed the informed consent form\n\n          -  Subject's parents commit to comply with the instruction\n\n        Exclusion Criteria:\n\n          -  Subjects concomitantly enrolled or scheduled to be enrolled in another trial\n\n          -  Evolving mild, moderate or severe illness, especially infectious diseases or fever\n             (axillary temperature >=37.5oC on Day 0)\n\n          -  Known history of uncontrolled coagulopathy or blood disorders contraindicating\n             intramuscular injection\n\n          -  Known history of allergy to any component of the vaccines (e.f. formaldehyde)\n\n          -  Known history of acquired immunodeficiency (including HIV infection)\n\n          -  Subject who has received a treatment likely to alter immune response in  the previous\n             4 weeks (e.g intravenous immunoglobulin, blood-derived products or long term\n             corticotherapy (>2 weeks)\n\n          -  Subject receives other vaccination within 1 month prior to inclusion\n\n          -  Any abnormality or chronic disease justified by investigator that might interfere\n             assessment of the trial objectives\n\n          -  Infant with a known history of diphtheria, tetanus, pertussis, Hepatitis B and Hib\n             infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "24 Months", 
            "minimum_age": "18 Months"
        }, 
        "enrollment": {
            "#text": "575", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095314", 
            "org_study_id": "Booster Penta 0413"
        }, 
        "intervention": {
            "arm_group_label": "Pentavalen", 
            "description": "Batch 5010613", 
            "intervention_name": "Pentavalen", 
            "intervention_type": "Biological", 
            "other_name": [
                "Pentabio vaccine", 
                "DPT-HB-Hib"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "DTP-HB-Hib", 
            "Pentavalen", 
            "Pentabio", 
            "Booster"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Kusnandi Rusmil, MD", 
                    "phone": "+62811232774"
                }, 
                "facility": {
                    "address": {
                        "city": "Bandung", 
                        "country": "Indonesia", 
                        "state": "West Java"
                    }, 
                    "name": "Ibrahim Adjie Primary Health Center"
                }, 
                "investigator": {
                    "last_name": "Meita Dhamayanti, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kusnandi Rusmil, MD", 
                    "phone": "+62811232774"
                }, 
                "facility": {
                    "address": {
                        "city": "Bandung", 
                        "country": "Indonesia", 
                        "state": "West Java"
                    }, 
                    "name": "Puter Primary Health Centre"
                }, 
                "investigator": {
                    "last_name": "Eddy Fadlyana, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kusnandi Rusmil, MD", 
                    "phone": "+62811232774"
                }, 
                "facility": {
                    "address": {
                        "city": "Bandung", 
                        "country": "Indonesia", 
                        "state": "West Java"
                    }, 
                    "name": "Garuda Primary Health Center"
                }, 
                "investigator": {
                    "last_name": "Adi Utomo, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hartono Gunardi, MD", 
                    "phone": "+6281310805050"
                }, 
                "facility": {
                    "address": {
                        "city": "Jakarta", 
                        "country": "Indonesia"
                    }, 
                    "name": "Mampang Prapatan Primary Health Center"
                }, 
                "investigator": {
                    "last_name": "Hindra Irawan, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hartono Gunardi, MD", 
                    "phone": "+6281310805050"
                }, 
                "facility": {
                    "address": {
                        "city": "Jakarta", 
                        "country": "Indonesia"
                    }, 
                    "name": "Jatinegara Primary Health Center"
                }, 
                "investigator": {
                    "last_name": "Bernie Endyarni, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hartono Gunardi, MD", 
                    "phone": "+6281310805050"
                }, 
                "facility": {
                    "address": {
                        "city": "Jakarta", 
                        "country": "Indonesia"
                    }, 
                    "name": "Tebet Primary Health Center"
                }, 
                "investigator": {
                    "last_name": "Rini Sekartini, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "1", 
        "official_title": "Antibody Persistence After Primary Doses, Immune Response and Safety After Doses of Pentabio Vaccine in Indonesian Children at 18-24 Months of Age", 
        "overall_contact": {
            "last_name": "Kusnandi Rusmil, MD", 
            "phone": "+62811232774"
        }, 
        "overall_contact_backup": {
            "last_name": "Hartono Gunardi, MD", 
            "phone": "+6281310805050"
        }, 
        "overall_official": [
            {
                "affiliation": "Department of Child Health, School of Medicine Padjadjaran University", 
                "last_name": "Kusnandi Rusmil, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Department of Child Health, School of Medicine, University of Indonesia", 
                "last_name": "Hartono Gunardi, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The number and percentage of children with anti diphtheria titer and anti tetanus titer >=0.01 IU/ml anti HBs >=10 mIU/ml, anti Hib >=0.15 ug/ml prior to booster administration.", 
            "measure": "Geomoteric mean titer prior to booster administration of Pentabio vaccine", 
            "safety_issue": "No", 
            "time_frame": "visit 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095314"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Serological response to diphtheria, tetanus, pertussis and Hib (Geometric Mean Titer)", 
                "measure": "Protectivity of Pentabio vaccine 1 month after the booster dose", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Geometric mean titer to diphtheria, tetanus, pertussis, Hepatitis B and Hib before immunization and 1 month after immunization", 
                "measure": "Serological response to diphtheria, tetanus, pertussis, hepatitis B and PRP-T before and 1 month after the booster dose", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "The changes of serological response before and after booster dose", 
                "measure": "Seroconversion and seroprotection before and 1 month after the booster dose", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Local and systemic reaction within 28 days after immunization.", 
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }
        ], 
        "source": "PT Bio Farma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PT Bio Farma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}